Mobile

'Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-line Therapy with Fludara plus Alentuzumab (CAMPATH, MabCampth) versus Fludara Alone in patients with B-Cell Chronic Lymphocyt...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000149-39

'Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-line Therapy with Fludara plus Alentuzumab (CAMPATH, MabCampth) versus Fludara Alone in patients with B-Cell Chronic Lymphocytic Leukemia' Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-line Therapy with Fludara plus Alentuzumab (CAMPATH, MabCampth) versus Fludara Alone in patients with B-Cell Chronic Lymphocytic Leukemia

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

to compare the efficacy of FluCam versus fludarabine phosphate alone based on the median time to disease progression (TTP) for the 2 treatment groups

Critère d'inclusion

  • Second line therapy with fludara plus Alentuzumab (Mabcampath) in Patient with b-cell Chronic Lymphocytic Leukemia,terapia di seconda linea in associazione Fludara con alentuzumab (Mabcampth) per il trattamento di pazienti affetti da Leucemia Linfocitica Cronica delle cellule B

Liens